You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence
Belimumab and the measurement of fatigue
Free
  1. Davide Mazzoni
  1. Correspondence to Dr Davide Mazzoni, Department of Psychology, University of Bologna, 47126 Cesena (FC), Italy; davide.mazzoni@unibo.it

https://doi.org/10.1136/annrheumdis-2015-207693

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with great interest the article by Strand et al.1 The aim of the study was to assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life in patients with active, autoantibody-positive SLE. Of particular interest are the results about the impact of belimumab on fatigue scores.

    Fatigue is a common complaint of patients with SLE and is associated with diminished ability to function.2 ,3 In the majority of cases, the cause of fatigue is still unexplained and it is likely that many factors together lead to lupus fatigue.2 However, until recently, clinical trials have not routinely assessed fatigue.3

    The article by …

    View Full Text

    Linked Articles